We take pride in our achievements and want to share our successes with you.
Updates on our latest news on ILB will be added as soon as it’s available.
8 February 2019
TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its…Read More
2 November 2018
First patient treated with ILB in TIKOMED’s clinical trial for ALS
Viken, November 2nd, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for…Read More
20 August 2018
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission
Viken, August 20th, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for…Read More
14 August 2018
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
VIKEN, Sweden, August 14, 2018 – TIKOMED, a specialty pharmaceutical company focused on developing therapeutics…Read More
24 July 2018
TIKOMED is looking for an experienced Project Leader
We are looking for you who are passionate, skilled and with strong track record and…Read More
5 July 2018
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
Viken, May 28th, 2018 TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating…Read More
5 July 2018
ILB – A game changer in Glaucoma
Viken, May 22nd, 2018 TikoMed, a specialty pharmaceutical company that focuses on developing therapeutics for…Read More